Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cytokinetics announced it granted stock options and restricted stock units to 8 new employees as a material inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). These grants include options to purchase 20,807 shares and 13,793 restricted stock units, with vesting schedules of 3 and 4 years respectively, subject to continued service. The company, a specialty cardiovascular biopharmaceutical firm, also highlighted its pipeline including MYQORZO® for oHCM and investigational medicines for heart failure.
MAY 15·AD HOC NEWS▲
Cytokinetics Inc stock (US2328281044): CLIMB muscle biology symposium adds to MYQORZO launch momentum
Cytokinetics Inc will host its third CLIMB muscle biology symposium on May 29, 2026, which is expected to extend the company's scientific and commercial momentum following the U.S. launch of MYQORZO and recent capital raises. The company's lead product, MYQORZO, a cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy, has already generated $4.8 million in early revenue and received approvals in Europe and China. Investors are closely watching the upcoming PDUFA action date on November 14, 2026, for additional regulatory milestones and potential market expansion.
MAY 10·Seeking Alpha→
Cytokinetics: Aficamten Has Momentum, But The Stock Is Too Expensive (NASDAQ:CYTK)
Cytokinetics has launched Myqorzo in the US, with promising early prescribing demand and positive Phase 3 trial results for aficamten in non-obstructive HCM. The company also has a strong cash position after a recent equity offering. However, the author finds the stock currently overvalued and suggests waiting for a dip before investing further.
